shelf(0)

No. 013 · GH & Growth · Growth Hormone

GHRP-2

PralmorelinKP-102GHRP-2

B Tier B · Small human studies how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
GHRP-2 (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER B — Human data limited to small, open-label or pharmacokinetic studies.

Human data are mainly small pharmacological and diagnostic studies; approved only in Japan as a GH-deficiency diagnostic.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
Other approvals
  • Japan — pralmorelin (GHRP Kaken 100) diagnostic for GH deficiency
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

A potent growth hormone releasing peptide that acts on the ghrelin receptor. It produces a strong GH pulse but may modestly increase cortisol and prolactin at higher doses.

Research status Well-characterized in clinical studies; published human pharmacokinetic and safety data

04

Mechanism

GHRP-2 is a synthetic hexapeptide that acts as a potent agonist of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) in the pituitary and hypothalamus. It stimulates GH release through both a direct pituitary action and by amplifying GHRH signaling, while also modestly activating the ghrelin appetite pathway.

05

Effects reported in research

Reported outcomes, not promises. Human data are limited to small studies, and many of these findings are preclinical.

  • Strong growth hormone pulse
  • Increased appetite stimulation
  • Enhanced deep sleep onset
  • Improved recovery from training
06

Safety & unknowns

Human study data available. Can elevate cortisol and prolactin at higher doses. Appetite stimulation may be unwanted. Common side effects: increased hunger, water retention, transient flushing. Not FDA-approved.

Unknowns. No randomized controlled trials have been published. Small studies cannot detect uncommon or long-term harms.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [0]

No studies cited for this entry yet.

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). GHRP-2. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/ghrp-2/

$ cite --format=bibtex 
@misc{peptidemeta-ghrp-2,
  title = {GHRP-2},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/ghrp-2/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open